675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Spero Therapeutics Enters Open Market Sale Agreement with Jefferies
Announces Second Quarter 2026 Operating Results and Provides Business Update
Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody, Investor Presentation
2026 Stock Incentive Plan Approved by Spero Therapeutics Stockholders
Utebzi approved in the US for adults with complicated urinary tract infections (cUTIs)
Announces First Quarter 2026 Operating Results and Provides Business Update
Annual Report to Security Holders
Financial Results, Press Release
Q2
Q1
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Confidential Treatment Order